Optimi Health submits clinical trial application after developing proprietary MDMA drug: Mugglehead Magazine

Author: Rowan Dunne, Mugglehead Magazine

Vancouver-based Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) has submitted a clinical trial application after successfully producing the first batch of a novel variety of MDMA designated as “OPTI-MHCL.”

The company said on Tuesday that it applied for the clinical trial and the proprietary new drug variation will enable it to become the number-one supplier of MDMA worldwide.

The news follows Australia announcing that it will be allowing the use of MDMA for medical purposes.

Optimi’s new drug will be used for clinical studies and treating patients authorized to access the psychedelic through Health Canada’s Special Access Program and Australia’s new Authorized Prescriber Scheme which comes into effect in July.

The upcoming study will be conducted in partnership with Calgary’s psychedelic therapy company, Atma Journey Centers

The clinical trial will also involve the study of a psilocybin extract the company has developed and Optimi has announced that it will be hosting an informative webinar about OPTI-MHCL on February 9.

Read more: Australia re-classifies MDMA and psilocybin to be prescribed as medicine

Read more: PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K.

Optimi’s Chief Science Officer Justin Kirkland also says the OPTI-MHCL MDMA that has been produced so far has a 99 per cent purity level.

“I am proud to say that we now have an optimized route for the delivery of MDMA using our own in-house technology which guarantees stable production and quality. We feel our proprietary MDMA is the way of the future, and this unique offering can position us as the number one supplier globally,” said Kirkland.

Optimi’s CEO Bill Ciprick says the demand for high-grade MDMA is continuing to increase as the American Food and Drug Administration gets closer to approving the use of the psychedelic for the treatment of PTSD.

The recently developed prescriber scheme coming into effect this summer in Australia is another catalyst for accelerating MDMA production as well, according to Ciprick.

Optimi’s stock price increased by 4 per cent on Tuesday to $0.26 on the Canadian Securities Exchange.

Source: Mugglehead Magazine




Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca


Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.


Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.